AU1112500A - Methods for inhibiting diabetic complications - Google Patents

Methods for inhibiting diabetic complications

Info

Publication number
AU1112500A
AU1112500A AU11125/00A AU1112500A AU1112500A AU 1112500 A AU1112500 A AU 1112500A AU 11125/00 A AU11125/00 A AU 11125/00A AU 1112500 A AU1112500 A AU 1112500A AU 1112500 A AU1112500 A AU 1112500A
Authority
AU
Australia
Prior art keywords
methods
diabetic complications
inhibiting diabetic
inhibiting
complications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11125/00A
Other languages
English (en)
Inventor
Billy G Hudson
Raja Gabriel Khalifah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas Medical Center Research Institute (KUMCRI)
Original Assignee
University of Kansas Medical Center
University of Kansas Medical Center Research Institute (KUMCRI)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas Medical Center, University of Kansas Medical Center Research Institute (KUMCRI) filed Critical University of Kansas Medical Center
Publication of AU1112500A publication Critical patent/AU1112500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU11125/00A 1998-10-14 1999-10-13 Methods for inhibiting diabetic complications Abandoned AU1112500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10427698P 1998-10-14 1998-10-14
US60104276 1998-10-14
PCT/US1999/023869 WO2000021516A2 (fr) 1998-10-14 1999-10-13 Procedes destines a empecher des complications diabetiques

Publications (1)

Publication Number Publication Date
AU1112500A true AU1112500A (en) 2000-05-01

Family

ID=22299580

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11125/00A Abandoned AU1112500A (en) 1998-10-14 1999-10-13 Methods for inhibiting diabetic complications

Country Status (2)

Country Link
AU (1) AU1112500A (fr)
WO (1) WO2000021516A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128295A1 (en) * 2000-11-02 2002-09-12 John Baynes Use of pyridoxamine for the treatment and inhibition of obesity-related complications
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
US8822542B2 (en) 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
US20080032990A1 (en) 2006-07-07 2008-02-07 Khalifah Raja G Inhibitors of advanced glycation end products
WO2011008202A1 (fr) * 2009-07-15 2011-01-20 Vanderbilt University Piégeurs d’isokétal et réduction des troubles impliquant une lésion oxydative
US20130017616A1 (en) * 2011-07-15 2013-01-17 Vanderbilt University - Center for Technology Transfer and Commercialization Methods For Treating Inflammation
EP3615015B1 (fr) * 2017-04-27 2024-03-13 Vanderbilt University Capteurs de gamma-cétoaldéhyde pour le traitement de l'athérosclérose
WO2021022215A1 (fr) 2019-08-01 2021-02-04 Khalifah Raja G Inhibiteurs de produits terminaux de glycation avancée

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2349330A1 (fr) * 1976-04-29 1977-11-25 Savini Emile Composition destinee au traitement des hyperlipidemies
DE3542309A1 (de) * 1985-11-29 1987-06-04 Cardona Federico Dr Medizinisches antioxidativum
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
KR920700632A (ko) * 1990-02-19 1992-08-10 요시다 쇼오지 메일라드 반응저해제
AU674330B2 (en) * 1992-06-30 1996-12-19 Howard K. Shapiro Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
JPH09221425A (ja) * 1996-02-13 1997-08-26 Taiho Yakuhin Kogyo Kk チオールプロテアーゼ阻害剤
JPH10158244A (ja) * 1996-12-02 1998-06-16 Kissei Pharmaceut Co Ltd ５−アミノアルキル−４−アミノメチル−３−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤
JPH10175954A (ja) * 1996-12-12 1998-06-30 Kissei Pharmaceut Co Ltd ４−アミノメチル−３−ヒドロキシピリジン誘導体およびそれらを含有するメイラード反応阻害剤
AU1444600A (en) * 1998-10-09 2000-05-01 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins

Also Published As

Publication number Publication date
WO2000021516A3 (fr) 2001-01-04
WO2000021516A2 (fr) 2000-04-20

Similar Documents

Publication Publication Date Title
AU6106999A (en) Process
AU3890299A (en) Cryo-sedimentation process
AU1749000A (en) Substrates for forming synthetic tissues
AU4438299A (en) Jackbolts for multi jackbolt tensioners
AU1647200A (en) Method for receiving spread-spectrum signals
AU5064499A (en) Method for determining hemoglobins
AU1424200A (en) Compounds
EP1127060B8 (fr) Procede de traitement aux borates hydrocarbones
AU4501699A (en) Aminoazole compounds
AU4523699A (en) Coalescer
AU1434500A (en) Compounds
AU1112500A (en) Methods for inhibiting diabetic complications
AU1223600A (en) Process
AU1055399A (en) Rollerboard
AU5223199A (en) Bathtub-bathseat
AU5661399A (en) Compounds
AU6794898A (en) Process for making phenol or phenol derivatives
AU4303799A (en) Gear
AU3715899A (en) Di-peroxy compounds
AU2845299A (en) Method for preparing 2-chloro-1-cyclohexyl-4-ethynylbenzene
AU6198599A (en) Method for forming drops
AU6353599A (en) Compound
AU1779099A (en) Heterocyclyl-derivatives
AU9218098A (en) Exocyclic-phosphoethanolamines
AUPP304698A0 (en) Process for demineralising

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase